Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Targeted Chemotherapy for Ovarian Cancer with Homologous Recombination
Deficiency of late relapse
Randomized clinical trial comparing liposomal doxorubicin plus carboplatin vs. paclitaxel plus carboplatin for recurrent, platinum-sensitive epithelial ovarian cancer with dysfunctional homologous
recombination pathway
Ting-Chang Chang, MD, MPHProfessor and Chairman, Chang Gung Memorial Hospitals, North TaiwanPresident, Taiwan Precision Medicine Society
Sensitivity and improved survival are hallmarks of BRCA-mutated and BRCA-ness EOC
• Attributed to the homologous recombination deficiency in the absence of BRCA1/BRCA2/RAD51 function• Impaired ability to repair DNA double strain breaks
• Increased sensitivity to • Cisplatin/carboplatin
• doxorubicin
• trabectedin
• mitomycin C
• etoposide
• topotecan
• irinotecan
CALYPSOROC relapsing > 6 months after first- or second-line therapyPegylated liposomal doxorubicin (30 mg/m2) and carboplatin (AUC 5) at 4-week intervals vs. paclitaxel (175 mg/m2) and carboplatin (AUC 5) at 3-week intervals
J Clin Oncol 28:3323-3329.Br J Cancer. 2012 Aug 7; 107(4): 588–591.
Eric Pujade-Lauraine et al. JCO 2010;28:3323-3329 British Journal of Cancer (2012) 107, 588–591
CALYPSO
MITO-2Chemotherapy-naïve, IC - IV ovarian cancer randomly assigned to carboplatin AUC 5 + paclitaxel 175 mg/m2 or to carboplatin AUC 5 + PLD 30 mg/m2, every 3 weeks for 6 cycles.
J Clin Oncol 28:3323-3329.Br J Cancer. 2012 Aug 7; 107(4): 588–591.
Sandro Pignata et al. JCO 2011;29:3628-3635
©2011 by American Society of Clinical Oncology
Study regimens and compliance in CALYPSO and MITO-2Regimen Compliance
MITO-2PLD 30 mg/m2 + Carbo AUC 5, every 3 wks
81% completed 6 cycles vs. 86% of control
34.5% of cycles delayed vs. 11.5% in control
CALYPSOPLD 30 mg/m2 + Carbo, AUC 5 every 4 wks 85% completed 6 cycles vs.
77% of control
21 wks of treatment duration vs. 16 wks in control
Control (both)Pacliaxel 175mg/m2 + Carbo AUC 5, every 3 wks
Hypothetical Distributions of BRCA mutation or BRCAnessin primary and in platinum-sensitive recurrent Epithelial Ovarian Cancer
Primary Platinum Sensitive Recurrent
Clinical trial proposal
• A Randomized, Open-label, Multicenter, Phase III Study to Compare the Efficacy of Liposomal Doxorubicin plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with BRCA-mutated Epithelial Ovarian Cancer of late relapse
• A Randomized, Open-label, Multicenter Study to Compare the Efficacy of Liposomal Doxorubicin plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with previously untreated BRCA-mutated Epithelial Ovarian Cancer
platinum-sensitive recurrent epithelial ovarian cancer
screening
BRCAm/BRCAness (-)/mis-match repair deficiency
Chemo-free period, 6-12 m or >12 m
stratification
Standard C/T Study C/T
Gemline BRCA1/2 mutated/Somatic BRCA1/2 mutated/BRCAness
Chemo-free duration, 6-12 m or >12 .
stratification
Standard C/T Study C/T
Testing for BRCAm/BRCAness
triage
BRCAm, pathogenic BRCA1/2 mutationR, randomizeStandard C/T, choose either paclitaxel 175 mg/m2 + carboplatin AUC5, every 3 wks x 6 or dose-dense paclitaxel 80 mg/m2/D 1,8,15 + carboplatin AUC5, every 3 wks x 6Study C/T, liposomal doxorubicin 30 mg/m2 + carboplatin AUC5 every 4 wks x 6
R R
• Comments